Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia.
N Engl J MedSep 17, 2026
Martin Schrappe, Franco Locatelli, Maria Grazia Valsecchi et al.
✦ AI-curated · Sources linked
In 30 seconds
This Phase III randomized controlled trial evaluated the efficacy of blinatumomab compared to traditional chemotherapy in children with newly diagnosed high-risk B-cell acute lymphoblastic leukemia (ALL). Among 709 randomized patients, the blinatumomab group demonstrated a 4-year event-free survival of 83.0% compared to 70.3% in the control group (P = 0.0002).
Key findings
- 4-year event-free survival was 83.0% in the blinatumomab group vs 70.3% in the control group (P = 0.0002).
- The estimated hazard ratio for a primary end-point event was 0.51 (95% CI, 0.35 to 0.73).
- Infection related to treatment occurred in 23.9% of the blinatumomab group vs 69.4% in the control group (P<0.001).
- Life-threatening adverse events occurred in 0.5% of the blinatumomab group vs 4.7% in the control group.
Why it matters
The findings suggest that blinatumomab may provide a safer and more effective alternative to traditional chemotherapy for pediatric patients with high-risk B-cell ALL, potentially reducing treatment-related morbidity.